Drug intelligence / Profile preview

TA-102

Development stage: Phase 1
Lead developer: Taro
Modality: Small Molecules
Administration: Topical

Overview

TA-102 is a topical small molecule drug developed by Taro Pharmaceuticals USA for the treatment of plaque psoriasis. It has been investigated in clinical trials for immune system diseases and skin and musculoskeletal diseases, with its primary indication being plaque psoriasis. The mechanism of action, specific targets, and active ingredient details have not been disclosed in public sources as of the latest updates. The drug has completed Phase 1 clinical trials assessing safety and potential for adrenal suppression following maximal use in subjects with plaque psoriasis[2][4].

Targets

DNATS (Thymidylate synthase)TYMP (Thymidine phosphorylase)

Beyond the preview

Go deeper on TA-102.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TA-102.

Explore the full profile